PHARMACEUTICAL IP

Biologics

At Evolve we have specialist knowledge of the unique requirements of IP strategy for large molecule pharmaceuticals and biologics, including therapeutic monoclonal antibodies, T-cell engagers (TCEs), antibody-drug conjugates (ADCs) and nucleic acid-based therapies.

We are dedicated to developing IP strategies that match the scientific and business vision for your products. The Evolve team provides a fantastic combination of both chemistry and biology scientific expertise that ensures that your innovations benefit from a high-level of IP protection.

Sector insights...

Alnylam v. Moderna and the judicious use of definitions: The European perspective

When drafting a patent, seemingly innocuous “boilerplate” definitions in the description can drastically narrow your claims, as demonstrated by the Alnylam v Moderna case in the US, highlighting the critical need for precise language to protect your invention.

Alexion’s Soliris sequence error saga (Alexion v Samsung Bioepis [2025] EWHC 1240)

Beware! The recent Samsung v Alexion UK High Court decision reveals that even a single-letter error in patent sequence data, coupled with vague descriptive language, can invalidate your claims and lead to costly legal battles.

First UPC decision to tackle infringement and validity of second medical claims (Sanofi v Amgen, UPC_CFI_505/2024)

Understand the UPC’s first ruling on second medical use patents, which clarifies novelty and infringement standards but creates new hurdles for patentees, especially concerning “skinny labelling” and proving off-label use.

Rose Hughes joins Evolve

Evolve Intellectual Property is pleased to welcome Dr. Rose Hughes as our new Patent Attorney.

Epitope claims stand firm: Board of Appeal upholds functional antibody patent despite insufficiency attack (T 0326/22)

The recent Board of Appeal decision T 0326/22 is yet further confirmation, if any were needed, that functionally-defined antibody claims remain viable at the EPO. In this decision, the Board of Appeal upheld Inhibrx’s European patent EP2812443 directed to a genus of anti-CD47 antibodies defined by their epitope binding and functional characteristics, finding both sufficient disclosure and inventive step. This decision once…

US Supreme Court decision in Amgen v Sanofi: The European Perspective

The US Supreme Court recently ruled in the high profile Amgen versus Sanofi patent dispute. Agreeing with the Federal Circuit (No. 20-1074, Fed. Cir. 2021), the Supreme Court found Amgen’s function and epitope defined PCSK9 antibody patents to lack enablement (Amgen Inc v Sanofi, No. 21-757). The US Supreme Court was keen to stress that its reasoning did…
View more Insights